IRF4 and neoplasm: For example, IRF1,14 IRF2,15 IRF3,16 IRF4,17 IRF718 and IRF819 intervene in PD‐1 blockade based immunotherapy and modulate the malignant progression of multiple tumours by regulating PD‐L1 expression.